



Rebased Historical Financial Information Reflecting the Group's 2026 Continuing Operations (FY2022- FY2025)



Re-presented Financials FY22-FY25 (Quarterly)

During the period FY2022 to FY2026, the Group has undertaken a number of strategic actions that have significantly altered the composition of the business. These include:

- The divestment of Wellnow (March 2025) and Fysiotest (December 2025), both of which have been classified as discontinued operations; and
- The closure of the clinic operations within the Champion Health Plus business, most recently completed in January 2026.

As a result of these changes, the Group's reported historical financial results are not directly comparable to the structure of the business as it is constituted from January 2026 onward.

To provide shareholders and investors with a meaningful basis for comparison, the following pro forma financial information for FY2022–FY2025 has been prepared. These figures adjust the previously reported results to:

- Remove the financial contribution of Wellnow and Fysiotest; and
- Remove the financial contribution of the Champion Health Plus clinic operations.

The resulting information reflects the historical performance of the Group's continuing operations as they are structured from January 2026.

This information is presented for illustrative purposes only and does not represent statutory financial statements. It should be read in conjunction with the Group's previously published annual reports and interim results.

The pro forma information has been prepared to enhance comparability and assist investors in assessing underlying performance trends. It does not reflect any forward-looking assumptions or synergies and is not intended to represent the Group's future financial performance.

€ Million Unless otherwise stated	FY 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Lifecare													
Annualised revenue	9.4	9.4	9.4	9.5	9.6	10.5	10.4	10.5	11.1	11.0	11.3	11.4	11.2
Total revenue	8.6	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.8	2.8	2.8	2.9	2.8
Subscription	7.4	2.1	2.1	2.2	2.3	2.6	2.5	2.6	2.7	2.7	2.8	2.8	2.8
Non-Subscription	1.3	0.3	0.3	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
% of recurring revenue	85%	87%	87%	91%	93%	99%	98%	100%	100%	99%	100%	98%	100%
Operating profit	2.7	0.6	0.5	0.5	0.4	0.6	0.5	0.4	0.3	0.5	0.7	0.7	0.7
D&A	1.6	0.5	0.6	0.6	0.7	0.7	0.7	0.7	0.8	0.8	0.7	0.7	0.7
Adjusted EBITDA	4.3	1.2	1.1	1.1	1.0	1.3	1.2	1.2	1.1	1.3	1.4	1.4	1.4
Adjusted EBITDA Margin %	49%	49%	47%	46%	43%	49%	46%	46%	41%	47%	50%	48%	50%
CAPEX	4.0	0.7	0.7	0.7	0.7	0.7	0.8	0.9	0.4	0.6	0.6	0.7	0.7
Adjusted EBITDA less CAPEX	0.2	0.5	0.4	0.4	0.4	0.5	0.4	0.2	0.7	0.7	0.8	0.7	0.7
Adjusted EBITDA less CAPEX Margin %	3%	21%	18%	17%	15%	20%	17%	10%	25%	25%	29%	23%	25%
Wellness													
Annualised revenue	1.2	0.3	0.3	0.2	0.3	1.8	1.8	2.0	1.9	1.6	1.6	1.6	1.4
Annualised revenue (recurring)	0.8	0.7	0.7	0.9	0.9	1.0	1.0	1.0	1.1	1.1	1.1	1.0	0.7
Total revenue	1.0	0.2	0.3	0.3	0.3	0.7	0.7	0.7	0.7	0.4	0.4	0.3	0.3
Subscription	0.5	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2
Non-Subscription	0.4	0.1	0.1	0.1	0.1	0.4	0.4	0.4	0.4	0.1	0.1	0.1	0.1
% of recurring revenue	54%	77%	70%	80%	76%	41%	38%	42%	45%	65%	70%	69%	66%
Operating profit	(0.3)	0.0	(0.0)	(0.1)	(0.1)	0.1	(0.0)	(0.1)	(0.1)	0.0	(0.1)	(0.1)	(0.2)
D&A	0.0	0.0	(0.0)	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Adjusted EBITDA	(0)	0	(0)	(0)	(0)	0	0	0	0	0	0	0	(0)
Adjusted EBITDA Margin %	-22%	22%	-2%	-10%	-9%	21%	8%	8%	5%	36%	3%	12%	-36%
CAPEX	0.2	0.1	0.2	0.1	0.2	0.1	0.1	0.0	0.4	0.0	0.1	0.0	0.1
Adjusted EBITDA less CAPEX	(0.4)	(0.1)	(0.2)	(0.2)	(0.2)	0.1	0.0	0.0	(0.3)	0.1	(0.0)	0.0	(0.2)
Adjusted EBITDA less CAPEX Margin %	-46%	-29%	-66%	-50%	-87%	13%	0%	0%	-49%	24%	-12%	3%	-57%
Group													
Operating profit	(2.6)	(0.7)	(0.7)	(0.7)	3.4	(0.6)	(0.7)	(0.6)	0.1	(0.8)	(0.6)	(0.8)	(6.3)
D&A	0.8	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.4	0.1
Adjusting Items	0.9	0.2	0.2	0.2	(3.8)	0.1	0.2	0.1	(0.6)	0.4	0.2	0.1	5.9
Adjusted EBITDA	(0.9)	(0.3)	(0.2)	(0.2)	(0.2)	(0.3)	(0.3)	(0.3)	(0.3)	(0.3)	(0.2)	(0.2)	(0.2)
Consolidated													
Annualised revenue	10.6	9.7	9.7	9.6	9.9	12.3	12.2	12.5	13.0	12.6	12.9	13.0	12.6
Annualised revenue (recurring)	10.2	10.1	10.1	10.4	10.5	11.4	11.4	11.5	12.1	12.1	12.3	12.4	11.9
Total revenue	9.6	2.6	2.6	2.7	2.7	3.3	3.3	3.2	3.4	3.1	3.2	3.2	3.1
Subscription	7.9	2.2	2.2	2.4	2.5	2.9	2.8	2.8	3.0	3.0	3.1	3.0	3.0
Non-Subscription	1.7	0.3	0.4	0.3	0.2	0.5	0.5	0.4	0.4	0.2	0.1	0.2	0.1
% of recurring revenue	82%	87%	85%	90%	92%	86%	86%	88%	89%	95%	96%	95%	97%
Operating profit	(0.2)	(0.0)	(0.2)	(0.3)	3.7	0.0	(0.2)	(0.3)	0.4	(0.3)	0.0	(0.1)	(5.8)
D&A	2.4	0.8	0.9	0.9	1.0	1.0	1.0	1.1	1.1	1.0	1.0	1.2	0.9
Adjusting Items	0.9	0.2	0.2	0.2	(3.8)	0.1	0.2	0.1	(0.6)	0.4	0.2	0.1	5.9
Adjusted EBITDA	3.1	0.9	0.9	0.9	0.8	1.1	1.0	0.9	0.9	1.2	1.2	1.2	1.1
Adjusted EBITDA Margin %	33%	36%	34%	32%	31%	34%	30%	29%	26%	37%	38%	37%	34%
Adjusted EBIT	0.7	0.1	0.0	(0.0)	(0.1)	0.1	(0.0)	(0.2)	(0.2)	0.1	0.2	(0.0)	0.1
CAPEX	4.3	0.8	0.8	0.8	0.9	0.8	0.8	1.0	0.8	0.7	0.6	0.8	0.8
Adjusted EBITDA less CAPEX	(1.1)	0.1	0.0	0.1	(0.1)	0.3	0.2	(0.0)	0.1	0.5	0.6	0.4	0.3
Adjusted EBITDA less CAPEX Margin %	-12%	6%	2%	2%	-2%	9%	5%	-2%	3%	16%	18%	14%	10%

Re-presented Financials FY22-FY25 (Quarterly aggregated)

€ Million Unless otherwise stated	FY 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Lifecare													
Annualised revenue	9.4	9.4	9.4	9.5	9.6	10.5	10.4	10.5	11.1	11.0	11.3	11.4	11.2
Total revenue	8.6	2.4	4.7	7.1	9.5	2.6	5.2	7.7	10.5	2.8	5.6	8.4	11.3
Subscription	7.4	2.1	4.1	6.3	8.6	2.6	5.1	7.7	10.4	2.7	5.5	8.3	11.1
Non-Subscription	1.3	0.3	0.6	0.8	1.0	0.0	0.1	0.1	0.1	0.0	0.0	0.1	0.1
% of recurring revenue	85%	87%	87%	89%	90%	99%	99%	99%	99%	99%	99%	99%	99%
Operating profit	2.7	0.6	1.1	1.6	2.0	0.6	1.1	1.5	1.9	0.5	1.2	1.9	2.7
D&A	1.6	0.5	1.1	1.8	2.4	0.7	1.4	2.1	2.9	0.8	1.5	2.2	2.8
Adjusted EBITDA	4.3	1.2	2.3	3.4	4.4	1.3	2.5	3.6	4.8	1.3	2.7	4.1	5.5
Adjusted EBITDA Margin %	49%	49%	48%	47%	46%	49%	48%	47%	46%	47%	49%	48%	49%
CAPEX	4.0	0.7	1.3	2.0	2.7	0.7	1.5	2.4	2.9	0.6	1.2	1.9	2.6
Adjusted EBITDA less CAPEX	0.2	0.5	0.9	1.3	1.7	0.5	1.0	1.2	1.9	0.7	1.5	2.2	2.9
Adjusted EBITDA less CAPEX Margin %	3%	21%	20%	19%	18%	20%	19%	16%	18%	25%	27%	26%	25%
Wellness													
Annualised revenue	1.23	0.32	0.32	0.17	0.29	1.82	1.80	2.01	1.88	1.61	1.64	1.63	1.40
Annualised revenue (recurring)	0.78	0.69	1.39	2.28	3.17	0.97	1.96	2.99	4.06	1.07	2.13	3.17	3.89
Total revenue	0.97	0.22	0.48	0.81	1.09	0.73	1.40	2.06	2.71	0.39	0.78	1.10	1.40
Subscription	0.52	0.17	0.35	0.61	0.83	0.30	0.56	0.83	1.13	0.25	0.53	0.75	0.95
Non-Subscription	0.45	0.05	0.13	0.19	0.26	0.43	0.84	1.22	1.58	0.13	0.25	0.35	0.45
% of recurring revenue	54%	77%	73%	76%	76%	41%	40%	41%	42%	65%	68%	68%	68%
Operating profit	(0.3)	0.0	0.0	(0.0)	(0.1)	0.1	0.0	(0.0)	(0.1)	0.0	(0.1)	(0.2)	(0.4)
D&A	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.3	0.4	0.1	0.2	0.4	0.5
Adjusted EBITDA	(0.2)	0.0	0.0	0.0	(0.0)	0.2	0.2	0.3	0.3	0.1	0.2	0.2	0.1
Adjusted EBITDA Margin %	-22%	22%	9%	1%	-1%	21%	15%	13%	11%	36%	19%	17%	6%
CAPEX	0.2	0.1	0.3	0.4	0.6	0.1	0.1	0.2	0.5	0.0	0.1	0.1	0.2
Adjusted EBITDA less CAPEX	(0.4)	(0.1)	(0.2)	(0.4)	(0.6)	0.1	0.1	0.1	(0.2)	0.1	0.0	0.1	(0.1)
Adjusted EBITDA less CAPEX Margin %	-46%	-29%	-49%	-49%	-59%	13%	7%	5%	-8%	24%	6%	5%	-9%
Group													
Operating profit	(2.6)	(0.7)	(1.4)	(2.1)	1.3	(0.6)	(1.3)	(1.9)	(1.8)	(0.8)	(1.4)	(2.2)	(8.4)
D&A	0.8	0.2	0.5	0.7	1.0	0.2	0.5	0.7	0.9	0.2	0.3	0.7	0.9
Adjusting Items	0.9	0.2	0.4	0.7	(3.2)	0.1	0.3	0.4	(0.2)	0.4	0.6	0.7	6.6
Adjusted EBITDA	(0.9)	(0.3)	(0.5)	(0.7)	(0.9)	(0.3)	(0.6)	(0.9)	(1.1)	(0.3)	(0.5)	(0.7)	(1.0)
Consolidated													
Annualised revenue	10.6	9.7	9.7	9.6	9.9	12.3	12.2	12.5	13.0	12.6	12.9	13.0	12.6
Annualised revenue (recurring)	10.2	10.1	10.8	11.7	12.8	11.4	12.4	13.5	15.1	12.1	13.4	14.5	15.0
Total revenue	9.6	2.6	5.2	7.9	10.6	3.3	6.6	9.8	13.2	3.1	6.3	9.5	12.7
Subscription	7.9	2.2	4.5	6.9	9.4	2.9	5.7	8.5	11.5	3.0	6.0	9.1	12.1
Non-Subscription	1.7	0.3	0.7	1.0	1.2	0.5	0.9	1.3	1.6	0.2	0.3	0.5	0.6
% of recurring revenue	82%	87%	86%	87%	88%	86%	86%	87%	88%	95%	95%	95%	96%
Operating profit	(0)	(0)	(0)	(1)	3	0	(0)	(0)	(0)	(0)	(0)	(0)	(6)
D&A	2.4	0.8	1.6	2.5	3.5	1.0	2.0	3.1	4.2	1.0	2.0	3.2	4.2
Adjusting Items	0.9	0.2	0.4	0.7	(3.2)	0.1	0.3	0.4	(0.2)	0.4	0.6	0.7	6.6
Adjusted EBITDA	3.1	0.9	1.8	2.7	3.5	1.1	2.1	3.0	3.9	1.2	2.4	3.6	4.6
Adjusted EBITDA Margin %	33%	36%	35%	34%	33%	34%	32%	31%	30%	37%	37%	37%	37%
Adjusted EBIT	0.7	0.1	0.2	0.1	0.0	0.1	0.1	(0.1)	(0.3)	0.1	0.4	0.3	0.5
CAPEX	4.3	0.8	1.6	2.4	3.3	0.8	1.6	2.6	3.4	0.7	1.3	2.1	2.8
Adjusted EBITDA less CAPEX	(1.1)	0.1	0.2	0.3	0.2	0.3	0.5	0.4	0.5	0.5	1.1	1.5	1.8
Adjusted EBITDA less CAPEX Margin %	-12%	6%	4%	3%	2%	9%	7%	4%	4%	16%	17%	16%	14%

Reclassified Financials FY25

1 January 2025 - 31 December 2025

Reclassified FY25 KPIs				
	3 Month period ended			
EUR millions (€m), unless otherwise stated	31-Mar-25	30-Jun-25	30-Sep-25	31-Dec-25
	Actual	Actual	Actual	Actual
Revenue	3.1	3.2	3.2	3.1
Lifecare	2.8	2.8	2.9	2.8
Wellness	0.3	0.4	0.3	0.3
Operating Expenses	(2.3)	(2.2)	(2.1)	(10.1)
EBITDA	0.8	1.0	1.1	(7.0)
Adjusting items	0.4	0.2	0.1	5.9
Adjusted EBITDA	1.2	1.2	1.2	1.1
Depreciation & Amortisation	1.0	1.0	1.2	0.9
EBIT	(0.3)	0.0	(0.1)	(5.8)
Adjusted EBIT	0.1	0.2	(0.0)	0.1
CAPEX	(0.7)	(0.6)	(0.8)	(0.8)
Adjusted EBITDA less CAPEX	0.5	0.6	0.4	0.3
Net cash from operating activities - continuing operations	1.0	0.8	1.3	1.4
Net cash from operating activities - discontinuing operations	(0.0)	(0.0)	(0.1)	0.2
Margins				
Adjusted EBITDA Margin (%)	37	38	37	34
Adjusted EBIT Margin (%)	4	8	(1)	4
Adjusted EBITDA less CAPEX (%)	16	18	14	10

Following the closure of all clinics relating to Champion Health Plus, in January 2026, this business line closure constitutes a discontinued operations in accordance with IFRS 5. Prior year comparatives have therefore been reclassified accordingly, with the reclassified quarterly 2025 key financial performance indicators presented above. The reclassified primary financial statements are shown on pages 5 to 7.

Reclassified Consolidated statement of comprehensive income

1 January 2025 - 31 December 2025

EUR (€)	Period Ended			
	31 March 2025 (Unaudited)	30 June 2025 (Unaudited)	30 September 2025 (Unaudited)	31 December 2025 (Unaudited)
<i>From continuing operations:</i>				
Revenue	3,139,787	6,331,774	9,526,868	12,662,436
Operating expenses before amortisation, depreciation and adjusting items	(2,012,162)	(3,999,209)	(5,984,548)	(7,945,241)
Amortisation and depreciation	(1,037,545)	(2,005,474)	(3,228,667)	(4,169,700)
Adjusting items	(388,387)	(603,157)	(722,534)	(6,638,224)
Operating loss	(298,307)	(276,066)	(408,881)	(6,090,729)
Finance income	3,871	11,792	16,967	22,075
Finance costs	(139,662)	(263,478)	(378,799)	(519,409)
Loss before taxation	(434,098)	(527,752)	(770,713)	(6,588,063)
Taxation	57,621	54,385	3,024	15,315
Loss after taxation of Continuing Operations	(376,477)	(473,367)	(767,689)	(6,572,748)
Loss from discontinued operations	48,278	(5,238)	(65,299)	(2,135,706)
Net loss after Taxation	(328,199)	(478,605)	(832,988)	(8,708,454)
Other Comprehensive Income which may be subsequently reclassified to the profit or loss - exchange differences on foreign operations	16,534	(355,022)	(577,587)	(501,550)
Total comprehensive loss for the year	(311,665)	(833,627)	(1,410,575)	(9,210,004)
Basic earnings per share (continuing operations)	(0.02)	(0.03)	(0.05)	(0.40)
Diluted earnings per share (continuing operations)	(0.02)	(0.03)	(0.05)	(0.40)
Basic earnings per share (total operations)	(0.02)	(0.03)	(0.05)	(0.54)
Diluted earnings per share (total operations)	(0.02)	(0.03)	(0.05)	(0.54)

Reclassified Consolidated statement of cash flows

1 January 2025 - 31 December 2025

	Period ended			
	Year ended 31 March 2025	Year ended 30 June 2025	Year ended 30 September 2025	Year ended 31 December 2025
	€	€	€	€
Operating activities				
(Loss)/profit for the period	(328,198)	(478,605)	(832,988)	(8,708,453)
Loss from discontinued operations	(48,279)	5,238	65,299	2,135,705
Depreciation and amortisation	1,037,545	2,005,474	3,228,667	4,169,700
Foreign exchange gain/(loss)	(6,436)	54,245	47,293	58,964
Taxation	(57,621)	(54,385)	(3,024)	(15,315)
Adjusting items	388,387	603,157	722,534	6,638,224
Net finance cost	135,791	251,686	361,832	497,334
Operating cash flows before movements in working capital	1,121,189	2,386,810	3,589,613	4,776,160
Increase in trade and other receivables	582,623	901,356	1,011,955	1,492,899
(increase)/decrease in inventory	-	-	-	2,774
(Decrease)/increase in trade and other payables and deferred revenue	(365,103)	(531,768)	(403,515)	(180,585)
Cash generated by operations before cash payment of adjusting items	1,338,709	2,756,398	4,198,053	6,091,248
Corporation tax paid	-	-	-	(13,546)
Cash payment of adjusting items	(388,387)	(998,124)	(1,125,615)	(1,582,551)
Net cash from operating activities - continuing operations	950,322	1,758,274	3,072,438	4,495,151
Net cash from operating activities - discontinuing operations	(25,059)	(41,553)	(91,066)	(314,613)
Net cash from operating activities	925,263	1,716,721	2,981,372	4,180,538

Reclassified Consolidated statement of cash flows

1 January 2025 - 31 December 2025

Investing activities:				
Purchases of intangible assets	(662,773)	(1,301,414)	(2,061,022)	(2,815,157)
Purchases of property, plant and equipment	(1,836)	(2,459)	(7,641)	(29,885)
Payment of deferred consideration	-	-	(87,735)	(263,205)
Net cash used in investing activities - continuing operations	(664,609)	(1,303,873)	(2,156,398)	(3,108,247)
Net cash used in investing activities - discontinuing operations	(27,017)	(28,534)	(34,850)	(38,076)
Net cash used in investing activities	(691,626)	(1,332,407)	(2,191,248)	(3,146,323)
Financial activities:				
Drawdown of borrowings	-	-	-	-
Repayment of borrowings	(538,123)	(437,372)	(592,572)	(713,292)
Loan extension fees	-	-	-	-
Funding to discontinued operations	(32,298)	(34,534)	(85,010)	(161,619)
Interest expense	(115,054)	(210,471)	(300,234)	(370,361)
Net cash generated by financing activities - continuing operations	(685,475)	(682,377)	(977,816)	(1,245,272)
Net cash generated by financing activities - discontinuing operations	33,230	53,517	85,942	161,728
Net cash generated by financing activities	(652,245)	(628,860)	(891,874)	(1,083,544)
Cash at the beginning of the period	723,386	723,386	723,386	723,386
Net movement	(418,608)	(244,546)	(101,750)	(49,329)
(Loss)/gain on exchange rate	(2,078)	(11,306)	(18,301)	(17,473)
Cash at the end of the period	302,700	467,534	603,335	656,584
Available facility	1,404,327	1,254,961	1,403,605	1,517,655
Available liquidity	1,707,027	1,722,495	2,006,940	2,174,239

